health-issue
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
https://ift.tt/7IHisUh from Sanofi - Aventis Groupe https://ift.tt/z2ouJMf via IFTTT
Read more
health-issue
Media Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma
https://ift.tt/5IzSWUl from Sanofi - Aventis Groupe https://ift.tt/2LMWYdk via IFTTT
Read more
health-issue
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
https://ift.tt/b4Tra1I from Sanofi - Aventis Groupe https://ift.tt/RyPeoAn via IFTTT
Read more
health-issue
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
https://ift.tt/n6MIarl Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation from Sanofi - Aventis Grou…
Read more
health-issue
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
https://ift.tt/9jREJP0 Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent D…
Read more
health-issue
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
https://ift.tt/CQreAx9 Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) from Sanofi - Aventis Groupe https:…
Read more
health-issue
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
https://ift.tt/OVXPp3M from Sanofi - Aventis Groupe https://ift.tt/7FdRqyh via IFTTT
Read more
health-issue
Media Update: New data presented at AAAAI highlight Sanofi’s scientific leadership across inflammatory diseases
https://ift.tt/hZ8fBmF New data presented at AAAAI highlight Sanofi’s scientific leadership across inflammatory diseases from Sanofi - Aventis Gro…
Read more
health-issue
Media Update: New data demonstrate clinical safety, benefit and durability of Nexviazyme® across a wide-range of Pompe disease patient groups
https://ift.tt/2hOuSPT New data demonstrate clinical safety, benefit and durability of Nexviazyme ® across a wide-range of Pompe disease patient gro…
Read more
health-issue
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
https://ift.tt/aqmnoeG from Sanofi - Aventis Groupe https://ift.tt/LQmnevN via IFTTT
Read more
health-issue
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
https://ift.tt/ANKp8mk Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology P…
Read more